G1 Therapeutics表示将终止其癌症治疗研究,因为安慰剂在后期试验中的表现优于药物,盘前股价跌逾50%。Teradata每股收益和营业收入均好于市场预期,并上调了下一季度和全年业绩展望,盘前股价大幅走高。日内经济数据清淡,投资者关注公司财报和美联储官员讲话。欧洲方面,旅游休闲类股领涨市场,欧洲主要股市全面走高。石油...
with G1 Therapeutics continuing as the surviving corporation and a wholly owned subsidiary of Pharmacosmos Therapeutics Inc., a U.S. subsidiary of Pharmacosmos A/S. In connection with the merger, all shares of G1 Therapeutics common stock (other than (i) shares...
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) --G1 Therapeutic...
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 4,700 shares of G1’s common stock and 2,300 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc....
G1 Therapeutics, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA®(trilaciclib). G1 has a deep cl...
先声药业(02096.HK)公布,于2022年7月12日,该集团与G1 Therapeutics, INC.(“G1”)合作的细胞周期蛋白依赖性激酶CDK4/6抑制剂科赛拉? (通用名:注射用盐酸曲拉西利)获国家药品监督管理局(“NMPA”)批准在中国附条件上市,用于既往未接受过系统性化疗的广泛期小细胞肺癌患者,在接受含铂类药物联合依托泊苷方案治疗...
GTHX is a biotechnology company that is focused on developing innovative therapies for the treatment of cancer.
The work was supported in part by the Microscopy and Flow Cytometry Core (MFCC) of the Center for Targeted Therapeutics at the University of South Carolina, Columbia, SC (2019-2021). Funding This research was supported by grant 075-15-2019-1661 from the Ministry of Science and Higher ...
These latter observations have advanced our understanding of NDRG1 function and how this molecule can be targeted by novel therapeutics. However, with respect to the wide spectrum of pathways that are affected by NDRG1, it remains to be established exactly how one molecule is able to achieve ...
G1 Therapeutics (NASDAQ: GTHX) Some price data may be temporarily unavailable. G1 Therapeutics Return vs. S&P 1 Year5 Year5 Year AnnualizedSince IPO GTHX +379.87% -79.89% -27.44% -52% S&P +8.41% +88.08% +13.47% +135% G1 Therapeutics Company Info G1 Therapeutics, Inc. engages in...